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Abstract
Purpose: Bolus electron conformal therapy (BECT) is a clinically useful, well-
documented, and available technology. The addition of intensity modulation (IM)
to BECT reduces volumes of high dose and dose spread in the planning target volume (PTV). This paper demonstrates new techniques for a process that
should be suitable for planning and delivering IM-BECT using passive radiotherapy intensity modulation for electrons (PRIME) devices.
Methods: The IM-BECT planning and delivery process is an addition to the
BECT process that includes intensity modulator design, fabrication, and quality assurance. The intensity modulator (PRIME device) is a hexagonal matrix of
small island blocks (tungsten pins of varying diameter) placed inside the patient
beam-defining collimator (cutout). Its design process determines a desirable
intensity-modulated electron beam during the planning process, then determines
the island block configuration to deliver that intensity distribution (segmentation). The intensity modulator is fabricated and quality assurance performed at
the factory (.decimal, LLC, Sanford, FL). Clinical quality assurance consists of
measuring a fluence distribution in a plane perpendicular to the beam in a water
or water-equivalent phantom. This IM-BECT process is described and demonstrated for two sites, postmastectomy chest wall and temple. Dose plans, intensity distributions, fabricated intensity modulators, and quality assurance results
are presented.
Results: IM-BECT plans showed improved D90-10 over BECT plans, 6.4% versus
7.3% and 8.4% versus 11.0% for the postmastectomy chest wall and temple, respectively. Their intensity modulators utilized 61 (single diameter) and 246 (five
diameters) tungsten pins, respectively. Dose comparisons for clinical quality assurance showed that for doses greater than 10%, measured agreed with calculated dose within 3% or 0.3 cm distance-to-agreement (DTA) for 99.9% and
100% of points, respectively.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2021 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in
Medicine.
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Conclusion: These results demonstrated the feasibility of translating IM-BECT
to the clinic using the techniques presented for treatment planning, intensity
modulator design and fabrication, and quality assurance processes.
KEYWORDS
bolus electron conformal therapy, electron beams, intensity modulation
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I NTRO DUCTI O N

To date three types of electron conformal therapy (ECT)
have been studied, bolus ECT (BECT), segmented-
field ECT, and modulated electron radiation therapy
(MERT).1 Each has advantages and disadvantages
compared with the others; however, only BECT technology is widely available in today's clinic. In BECT, a
variable thickness bolus abutting the patient surface
is used to modulate laterally the therapeutic range, for
example, R90, so that the 90% dose surface conforms
to (circumscribes) the patient planning target volume
(PTV). BECT offers the potential for lower whole body
dose, reducing secondary cancer risks, and equal or
lower dose to nearby critical structures, reducing normal tissue complications, as compared to that of intensity modulated x-ray therapy (IMXT).
Historically, electrons have been an important modality for (1) the treatment of skin, lip, head, and neck
tumors, (2) boost doses to superficial lymph nodes,
and (3) postmastectomy chest wall irradiation. 2– 5
Since the onset of 3D treatment planning, BECT has
been shown useful for posterior chest wall 6–8; postmastectomy chest wall7,9–11; ear, parotid, and buccal
mucosa7,12; nose13; and extremities (hand and foot).8
As a result, BECT is currently available from two
companies that provide bolus design software, which
integrate with one's treatment planning system,8,14
and bolus fabrication methods (milled or printed).6,8
The typical BECT treatment and delivery process
consists of patient immobilization, CT scanning, PTV and
normal tissue delineation, beam design, bolus design,
dose calculation, bolus fabrication, and quality assurance.6 Bolus design is typically an iterative optimization
process.8,14 Physical quality assurance following fabrication can be made by bolus thickness measurement
at multiple off-axis locations. Clinical, dosimetric quality
assurance can be made using a repeat CT scan from a
CT simulator or pre-treatment cone beam CT to perform
a patient dose calculation with bolus in place.6,13
Clinical experience has demonstrated that in some
cases, the upstream bolus surface is sufficiently irregular
to cause undesirable dose heterogeneities in the PTV, that
is, volumes of increased dose (hot spots) and decreased
dose (cold spots). However, Kudchadker et al.7 showed

that the introduction of modest intensity modulation (70%–
100%) across the beam, followed by moderate redesign of
the bolus, can significantly reduce PTV dose heterogeneity while maintaining a dose distribution conformal to the
PTV. Hence, intensity modulated BECT, that is, IM-BECT,
can conform the therapeutic dose surface (e.g., 90%) to
the distal PTV surface, while producing a reasonably uniform dose in the PTV (≈10%–15% dose spread).
Recently, Hogstrom et al.15 developed a simple, potentially economical method for design and fabrication of
a passive radiotherapy intensity modulator for electrons
(PRIME) device,16 analogous to the utilization of x-ray compensators for IMXT prior to the widespread availability of
x-ray multi-leaf collimators (MLCs).17,18 The objective of this
paper is to describe a process that should be suitable for
planning and delivery of IM-BECT. The process, detailed
and demonstrated for two patient sites, includes adding
techniques for design, fabrication, and quality assurance of
the intensity modulator19,20 to the current BECT process.6
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Methods for planning and delivering IM-
BECT are
demonstrated using data from two patients previously
treated using BECT. For each patient, treatment planning was done using research versions of a BECT
bolus design system in which the ability to utilize intensity modulators was added. The intensity modulators
(PRIME devices) resulting from the treatment plans
were fabricated, then the process of clinical quality
assurance of the fabricated intensity modulators was
demonstrated by comparing dose calculations with
measurements beneath the intensity modulators in a
water phantom. Planning and delivery techniques, that
is, bolus and intensity modulator design, patient dose
calculation, fabrication of intensity modulator, and quality assurance, are presented.

2.1 | Patient data
Two anonymized patient CT data sets (HIPAA compliant) were selected for two sites, postmastectomy
chest wall and temple. Each patient had been treated
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previously with BECT. Chest wall and head and neck
patients were selected because such patients have
shown moderately and significantly improved PTV
dose homogeneity when using IM-BECT as opposed
to BECT (Kudchadker et al.,7 Doiron21). This study used
the planning target volumes (PTVs), normal tissues,
and structures previously contoured by radiation oncologists and medical dosimetrists (cf. Figure 1).

2.2 | Treatment planning
The patient plans for this study were developed using
the Pinnacle3 treatment planning system (Philips) and
research versions of the p.d bolus design system22
(.decimal, LLC). The beam geometry (gantry, couch,
and collimator angles; source to surface distance, SSD;
and table and isocenter locations), block aperture, and
beam energy for each patient's previous BECT treatment, and the PTV outlines, structure outlines, and CT
data for each patient were inputted from Pinnacle3 into
the p.d software using DICOM transfer. For both patients
the selected beam energy was 16 MeV (R90 = 5.0 cm).
The p.d software system designed the bolus and intensity modulator and calculated the dose distribution
for each patient IM-BECT plan. This process can be
done in approximately 2 hours by a treatment planner
competent with the IM-BECT planning process and p.d
software. Details of this treatment planning process
and how it differs from a BECT treatment planning process are presented as follows.

2.2.1 | Initial bolus design
For each patient, a conformal bolus was designed
using the clinical version (v5.1) of p.d.22 The bolus was
designed such that the 90% dose surface conformed
to (circumscribed) the distal PTV surface. The design
process used a sequence of operators that created,
modified, and extended the bolus. The Create (physical
depth), Isodose Shift, Smooth, and Height Extension

F I G U R E 1 3D rendering of the
postmastectomy chest wall (left) and
temple (right) patient data used in current
demonstration. The renderings show
the skin surface, planning target volume
(aqua), electron collimating insert (yellow),
and electron beam (gray)
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operators were those of Low et al.,14 and the specified shift operator shaved or added a specified uniform
thickness to the bolus. The operators were used in sequences which best achieved the treatment planning
goals, namely that the 90% isodose surface circumscribed the PTV. The Truncate operator removed upstream bolus surface outside the field to reduce bolus
weight, having no impact on the dose distribution. The
sequences of operators used to design the initial patient bolus for each patient are listed in Table 1.

2.2.2 | Initial intensity modulator design
After completing the initial bolus design, the intensity
modulation operator was applied to create greater
dose homogeneity within the patient by reducing dose
greater than 100% (hot spots, as dose typically is prescribed to 90%). These IM-BECT treatment plans were
created in a research version of p.d, which included an
additional intensity modulation operator, as described
by Hilliard.20 The intensity modulation operator requires
the user to choose a limit to the maximum and minimum intensity reduction factors (IRFs). The program
then designs an intensity map (IRF versus off-axis position) based on the dose distribution resulting from the
initial bolus design.
Because of a small interdependence of the bolus
and intensity modulator,7 to achieve better patient plans
the bolus requires reoptimization following application
of the intensity modulation operator. The research version of p.d used for the initial intensity modulator design
and fabrication did not allow for bolus reoptimization,
but was sufficient for early bolus fabrication and QA
measurements. A subsequent research version of p.d,
which included bolus reoptimization, was used to generate the final dose distributions used to evaluate patient plans. Although the two research versions differed
slightly, differences in their designed intensity modulators were clinically insignificant (<1%).
The sequences of operators used to design the fabricated intensity modulators are shown in Table 1. The
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Post-mastectomy chest wall
patient
1. Create (90%, 0.7 cm)
2. Smooth (2,1)
3. Isodose Shift (0.5 cm)
4. Smooth (2,1)
5. Isodose Shift (0.5 cm)
6. Smooth (2,1)
7. Truncate
8. Specified Shift (−0.1 cm
BECT, −0.3 cm IM-BECT)
9. Intensity Modulation

Temple patient
1. Create (90%, 0.7 cm)
2. Smooth (2,1)
3. Isodose Shift (0.5 cm)
4. Smooth (2,1)
5. Isodose Shift (0.5 cm)
6. Smooth (2,1)
7. Truncate
8. Specified Shift (−0.2 cm BECT, −0.4 cm IM-BECT)
9. Intensity Modulation

TA B L E 1 Sequence of p.d operators
(parameters in parenthesis) used to
design a bolus and intensity modulator for
each patient 22

The resulting intensity modulators were fabricated for QA measurements. The BECT operator sequence
(un-bolded steps) was followed by the intensity modulation sequence (bolded step). The Create operator
input parameters are the percent dose (90%) being conformed to the distal PTV and the distance inside
the PTV edge (0.7 cm) in which the bolus is created based on physical depth; the Smooth operator input
parameters are a multiplier (2) in the exponent of a Gaussian function and a multiplier (1) of a 1.5-cm
radial distance over which the smoothing of the bolus height occurs; the Isodose Shift operator input
parameter is the distance inside the PTV edge (0.5 cm) in which the bolus thickness is increased or
decreased to shift the depth of the 90% dose surface within the patient; and the Specified Shift operator
input parameter (−0.1 or −0.2 cm) is the thickness subtracted from the entire proximal bolus surface.
Truncate minimizes the bolus mass by reducing the flat, upstream bolus surface outside the treatment
field, having no impact on the dose distribution.

TA B L E 2 Sequences of p.d operators (parameters in
parenthesis) used for comparing BECT and IM-BECT patient plans.
BECT plans used the operator sequence (non-bolded steps);
IM-BECT plans used the same BECT sequence plus the intensity
modulation and bolus reoptimization sequence (bolded steps)
Post-mastectomy chest wall
patient
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.

Create (90%, 0.5 cm)
Smooth (2,1)
Isodose Shift (0.5 cm)
Smooth (2,1)
Isodose Shift (0.5 cm)
Smooth (2,1)
Truncate
Specified Shift (−0.1 cm)
Intensity Modulation
Isodose Shift (0.5 cm)
Smooth (2,1)
Specified Shift (−0.1 cm)

Temple patient
1. Create (90%, 0.7 cm)
2. Smooth (2,1)
3. Isodose Shift (0.5 cm)
4. Smooth (2,1)
5. Isodose Shift (0.5 cm)
6. Smooth (2,1)
7. Truncate
8. Specified Shift (−0.2 cm)
9. Intensity Modulation

sequences of operators used for the final patient plans,
which includes bolus reoptimization are shown Table 2.
Bolus reoptimization was not required for the temple
patient.

Modification of pencil beam weights
The intensity modulation operator modifies the weight
of each pencil beam by looking at the maximum dose
along each ray line from the beam's virtual electron
source (assumed 100 cm from isocenter) through the
center of each pencil beam, which falls a specified
margin (0.5 cm) inside the edge of (the PTV.
The pencil
)
beam weight along the i,j fan line wi,j is modified so
that
( )
( )
wi,j new = wi,j old ∗ IRF,

(1a)

where
IRF = 1.000 for Dmax (i, j) < 100 %,

(1b)

IRF = 100 %∕Dmax (i, j) for 100% ≤ Dmax (i, j) ≤ 80−1 % ,
(1c)
IRF = 0.800 for Dmax (i, j) > 80%−1 ,

(1d)

where Dmax (i, j) is the maximum percent dose along the
(i, j) pencil beam ray-line, and the intensity reduction
factor (IRF) was limited to the range from 0.8 to 1.0.
Pencil beam weights for pencil beams with ray-lines
outside of the specified margin were determined using
the same method Low et al.14 used for bolus height
extension.

Segmentation of pencil beam weights into island
blocks
Similar to an x-ray intensity modulated field being segmented into an MLC leaf sequence, the intensity map of
the “new” beam weights was segmented into an island
block pattern that closely achieved that intensity map.
The segmentation process was based on an algorithm
developed by Chambers.19 It takes the initial island block
pattern, determined using the method described below,
then calculates the underlying intensity pattern using a
pencil beam algorithm.23 After comparing the calculated
with the desired intensity pattern, island block diameters
are modified. This process, which iterates until results
meet an optimization criteria, is shown schematically in
Figure 2.
In the current study, only the initial step in the chambers optimization algorithm was used. Island blocks were
placed on a 0.6-cm hexagonal grid (specified at 93.5 cm
source to collimator distance). For each grid point on the
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F I G U R E 2 Workflow for the electron intensity modulator generator software. An initial block matrix using equation (2) is generated
and tested using pre-established criteria. Points of failure are improved iteratively until criteria are met or minimized. Abbreviations: PBA is
pencil beam algorithm; BM is Block Matrix

TA B L E 3 Available tungsten island
block diameters d and corresponding IRF
values when used with 0.6 cm hexagonal
spacing r

d (cm)

0.158

0.223

0.273

0.315

0.352

0.386

0.417

0.473

IRF (%)

93.7

87.5

81.2

75.0

68.8

62.5

56.2

43.6

hexagonal grid the algorithm first calculated the island
block diameter d based on fraction of area blocked using15
� √
�1∕2
2 3
d (r , IRF) = r
,
(1 − IRF)
𝜋

(2)

where r is the distance separating the hexagonally packed
circular island blocks of diameter d, and IRF is the intensity reduction factor, which equals the ratio of the desired
underlying intensity (to that
) in the absence of the intensity
modulator, that is, wi,j . Then, the algorithm selected
an island block diameter closest from a set of available
tungsten island block diameters (cf. Table 3). The resulting island block patterns were sent to the p.d bolus design
system for the final dose calculation and to .decimal for
fabrication of the intensity modulator.

2.2.3 | Dose calculation using the pencil
beam redefinition algorithm (PBRA)
For its electron beam dose calculations p.d bolus design
software utilizes the pencil beam redefinition algorithm
(PBRA), developed originally by Shiu and Hogstrom24
and improved by Boyd et al.25 to include a polyenergetic, incident electron beam. Dose at each point (x, y,
z) is the sum of the electron beam component (De) and
the background x-ray dose component (DX ), that is,
D (x, y, z) = De (x, y, z) + DX (x, y, z) ,

(3)

where the x-ray dose calculation uses an empirical, data
based model described by Shiu.26 The electron dose

calculation transports the phase space of the electron
pencil beams at z to pencil beams at z + Δz modelling
collisional energy loss, multiple Coulomb scattering, and
beam divergence.
The PBRA was extensively validated by Boyd et al.27
using a measured data set by Boyd et al.28 for a number
of patient-like geometries and using Monte Carlo calculations for multiple patient sites.29 The PBRA was also
validated in anthropomorphic phantoms for use with
BECT by Carver et al.30

Changes to the PBRA for intensity modulators
For dose calculations with the passive intensity modulators containing island blocks, used in this study,
three modifications were made to the PBRA: (1) reducing the energy of the beam to decrease R90 by
0.1 cm, which accounts for energy loss in the 1.27-
cm thick machinable foam (ρ = 0.096 g cm−3) containing the island blocks, (2) increasing the initial
angular spread 𝜎 𝜃x by 50% to account for additional
scatter in the machinable foam, and (3) modelling the
effect of the island blocks removing electrons from
the beam. Details of the former two are described by
Hilliard. 20
The third modification of the PBRA code accounted for the reduction in electron fluence
reaching the bolus surface due to the island blocks
embedded in the intensity modulator's machinable
foam. It was assumed that all electrons incident on
the top surface of the island blocks are removed
from the beam. This required modifying only the
first step of the PBRA, which transports electron
fluence from the plane of the collimator to the surface of the bolus (or patient). Each circular island

6
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block was modelled as a square pencil beam of
equal area, whose electrons were transported to
the surface of the bolus (or patient) with negative
fluence.
This concept, illustrated in Figure 3, determines the
fluence at the starting pixel for the first pencil beam
along each (i, j ) ray line, which is given by
intensity modulated beam

𝜙i,j

without island blocks
= 𝜙beam
i,j

−

# blocks
∑

𝜙li,j

, (4)

l=1

where

𝜙li,j

is the fluence that would be contributed by

electrons striking the lth block in its absence to the (i, j )
pencil beams. This approximation ignored (1) electrons
scattered into or out of the sides of the island blocks,
that is, assumes perfect collimation, and (2) any
changes to the bremsstrahlung dose caused by the island blocks.

2.3 | Intensity modulator fabrication
Once the intensity modulators (PRIME devices)
were designed, they were fabricated by .decimal
using the following procedure. First, a standard
patient-s pecific 1.48-c m thick copper cutout was
machined. Second, a 1.27-
c m thick machinable
foam insert matching the shape of the copper cutout was machined, and holes with axes following
diverging rays from the virtual source were drilled
0.9 cm deep with the appropriate diameter to
match the designed island block at the locations
on the hexagonal grid having island blocks. Third,
the milled machinable foam block was press-f itted
into the copper cutout. Fourth, the appropriate
diameter 0.6-c m long tungsten pin was manually
inserted into each hole, completing the device.
The entire process took approximately 2 hours, although some manual steps could be automated in
the future.

2.4 | Intensity modulator
quality assurance
IM-
BECT requires at least three patient-
specific devices: wax bolus, electron cutout, and intensity modulator (occasionally skin collimation, internal collimation,
or eye blocks are also used). Wax bolus quality assurance (QA) is the same for IM-BECT as for BECT,
which presently, is typically achieved by factory measurements and clinical acquisition of either a simulation
CT scan with bolus1,6 or pre-treatment cone-beam CT
scan.13 Alternatively, the clinical QA could be a CT scan
of the bolus. This section focuses on quality assurance
for the intensity modulator, which by its nature also provides quality assurance of the collimating cutout that
contains the intensity modulator.

2.4.1 | Factory quality assurance
The objective of factory quality assurance was to ensure
that the correct diameter island blocks were inserted into
the machinable foam substrate at the correct locations
on the hexagonal grid. This was achieved by capturing
an image of the intensity modulator (cf. Figure 4) using
an optical scanner. A software program then used lines
scored on the copper cutout that demarcate the beam
orthogonal axes to determine planned locations of island blocks on the specified hexagonal grid. Second,
the software validated the presence or absence of an
island block. Third, the proper island block diameter was
manually verified. Following factory quality assurance,
the copper cutout-intensity modulator was shipped to
Mary Bird Perkins Cancer Center (MBPCC).

2.4.2 | Clinical quality assurance
The clinical quality assurance (QA) process mimics
that used for x-ray intensity modulation (generated by
either a metal compensator or multi-leaf collimator) in
which the underlying intensity pattern is measured in

F I G U R E 3 Schematic drawing
showing how the PBRA code incorporated
island blocks into the dose calculation for
intensity modulated electron beams using
the passive intensity modulators with
island blocks
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planar dose ASCII files exported from Pinnacle3 contained a grid of calculated dose with pixel sizes of
0.1 cm.

F I G U R E 4 Optical scan of temple intensity modulator used
for factory quality assurance. Shown is the custom copper cutout
containing tungsten island blocks inserted into the machinable
foam

a plane perpendicular to beam central axis. In the present study, measurements were made at 0.5 and 2.0-
cm depths in a water phantom at 100-cm SSD using a
scanning diode. These measurements were then compared with the PBRA calculated off-axis dose distributions generated in p.d after replacing the patient and
bolus with a water phantom. Our objective was to verify
that the patient-specific intensity modulator delivered a
relative fluence (dose) distribution within 3% or 0.3 cm
of that calculated by the PBRA.

Calculation of dose distributions downstream of
patient intensity modulators
Relative dose (fluence) distributions were calculated
using a research version of p.d. The dose was normalized such that 100% equaled the “given dose” without
the intensity modulator. “Given dose” is the maximum
central axis dose in water, Dmax at R100, for the patient's
effective field size (rectangular field with minimum area
that circumscribes the irregular patient field), energy,
and SSD. SSD was the distance from a point 100 cm
upstream of isocenter to the bolus surface on central
axis.
For comparison to measured dose distributions, the
dose distributions were calculated in a water phantom with the patient intensity modulator (device cutout
and island block pattern) for each patient. The dose
was then transferred from p.d to the Pinnacle3 (v9.10
Philips) treatment planning system so that planar dose
distributions could be exported to a laptop computer
using MATLAB software (R2016, MathWorks). The

Dose measurement downstream of patient intensity
modulators
Off-
axis profiles were measured using an electron
diode in a Blue Phantom2 (IBA Dosimetry) 3D scanning
system; a CC13 ion chamber was used as the reference detector. The detectors were connected to a beam
scanning common control unit (CCU), which contained
two internal electrometers. The water phantom servo
and CCU were controlled using the OmniPro-Accept
scanning software (v7, IBA Dosimetry). The water surface was set to 100-cm SSD. Planar dose measurements were made at depths of 0.5 and 2.0 cm in water.
Details of phantom setup are standard and have been
reported by Hilliard.20
All measurements were performed on an Elekta
Infinity accelerator, whose commissioned central-
axis depth doses were used by the PBRA. Measured
doses were normalized in the identical manner as was
the calculated dose with 100% equaling the “given
dose”.
Methods for comparing calculated and measured
dose distributions
The calculated and measured planar dose distributions
were compared using isodose plots at the two measured
depths (0.5 cm and 2.0 cm) for the intensity modulator
of each of the two IM-BECT treatment plans. Results at
2.0 cm are recommended for clinical QA and are presented here; results at 0.5 cm were similar and are reported
by Hilliard.20 The percent dose difference and distance to
agreement (DTA) between the calculated and measured
distributions were calculated, where the DTA is defined as
the distance from the point being examined and the closest
point where the dose distributions have the same value. All
points receiving at least 10% of the maximum dose were
included in the percent dose difference/DTA analysis.

3
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3.1 | Patient treatment plans
The chest wall patient's IM-BECT dose distribution is
plotted for selected CT planes in Figure 5a–c. The sagittal plane demonstrates PTV coverage with respect to
the heart and lung; the two transverse planes further
demonstrate PTV coverage in planes through the heart
and through the lungs. Figure 5d compares PTV, lung,
and heart dose volume histograms (DVHs) for the IM-
BECT and BECT plans. DVHs were normalized such
that the V95 for the PTVs match between the BECT and
IM-BECT plans. The IM-BECT PTV DVH shows dose
homogeneity improved from that of the BECT plan; the

8
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F I G U R E 5 Chest wall patient CT
planes showing the PTV (teal) and
isodose lines (90% is yellow) for IM-BECT
treatment plan. The bolus is shaded blue.
(a) Sagittal plane containing the central
axis of the beam; dashed lines indicate
positions of axial planes. Axial planes are
(b) 3.5 cm superior (lung) and (c) 3.5 cm
inferior (heart) to the central axis of the
beam. (d) PTV, heart, right lung, and
left lung DVHs for IM-BECT and BECT
treatment plans

(b)

(c)
(d)

D90-10 is reduced from 7.3% to 6.4%, and the maximum
PTV dose is reduced from 103.6% to 101.4%. These
are due to reducing the intensity inferiorly and laterally.
The temple patient's IM-BECT dose distribution is
plotted for selected CT planes in Figure 6a–c. The sagittal plane demonstrates PTV coverage with respect to
the temple and brain; the two transverse planes further demonstrate PTV coverage in planes through the
right eye and brain. Figure 6d compares PTV DVHs for
the IM-BECT and BECT plans. DVHs were normalized
such that the V95 for the PTVs match between the BECT
and IM-BECT plans. The IM-BECT DVH shows dose
homogeneity improved from that of the BECT plan; the
D90-10 is reduced from 11.0% to 8.4%, and the maximum PTV dose is reduced from 118.6% to 109.8%.
These are due to reducing the intensity over the thinner
regions of the bolus, which had underlying hot spots
without intensity modulation.

3.2 | Intensity modulator design and
fabrication
The isointensity distribution determined in the treatment
planning process for the chest wall patient is mapped in

Figure 7a. The range of intensity modulation was small
in this case (0.94–1.00). It was mostly needed in the
vicinity of the medial, inferior border of the field, due to
angled incidence and shorter SSD of the patient there.
This isointensity distribution was used to determine the
island block distribution, which is shown in Figure 7b.
The resulting isointensity distribution created by the
island blocks is illustrated in Figure 7c by plotting the
PBA-calculated relative fluence distribution at a 0.5-cm
depth in a water phantom at 105 cm SSD. A photograph of the intensity modulator fabricated by .decimal
is shown in Figure 7d. This intensity modulator required
only 61 island blocks (all 0.158 cm diameter) placed at
the specified locations on a 0.6-cm hexagonal grid.
Similarly, the isointensity distribution determined in
the treatment planning process for the temple patient is
mapped in Figure 8a. The range of intensity modulation
was moderate in this case (0.82–1.00). It was mostly
needed in the inferior portion of the anterolateral PTV
region where the bolus was thinnest. Here, in-scatter
from the surrounding thicker portions of the bolus,
which created considerable variability (gradients) of
the bolus surface, resulted in hot spots. This isointensity distribution was used to determine the island block
distribution, which is shown in Figure 8b. The resulting
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F I G U R E 6 Temple patient CT planes
showing the PTV (teal) and isodose lines
(90% is yellow) for IM-BECT treatment
plan. The bolus is shaded blue. (a)
Sagittal plane containing the central
axis of the beam; dashed lines indicate
positions of axial planes. Axial planes are
(b) 3.0 cm inferior (R eye and brain) and
(c) 3.0 cm superior (brain) to the central
axis of the beam. (d) PTV, right eye, right
lens, and right parotid DVHs for IM-BECT
and BECT treatment plans

F I G U R E 7 (a) Chest wall objective
isointensity map as calculated by p.d
(b) Pin pattern design resulting from
segmentation of objective intensity
map as described in Section 2.2.2. (c)
PBA-calculated intensity map based on
pin pattern. (d) Photograph of intensity
modulator fabricated for the chest wall site
IM-BECT treatment plan. (-X is medial; -Y
is inferior)

isointensity distribution created by the island blocks is
illustrated in Figure 8c by plotting the PBA-calculated
relative fluence distribution at a 0.5-cm depth in a water

phantom at 105 cm SSD. A photograph of the intensity
modulator fabricated by .decimal is shown in Figure 8d.
This intensity modulator required 246 island blocks (1

10
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F I G U R E 8 (a) Temple objective
isointensity map as calculated by p.d
(b) Pin pattern design resulting from
segmentation of objective intensity
map as described in Section 2.2.2. (c)
PBA-calculated intensity map based on
pin pattern. (d) Photograph of intensity
modulator fabricated for the temple
IM-BECT treatment plan. (-X is medial/
anterior; -Y is inferior)

at 0.352, 1 at 0.315, 7 at 0.273, 17 at 0.223, and 220 at
0.158 cm diameter) placed at the specified locations on
a 0.6-cm hexagonal grid.

3.3 | Quality assurance of intensity
modulator and bolus
Quality assurance of the intensity modulator at both the
factory and clinical site occurred. Factory quality assurance used optical scanned images (similar to photographs in Figures 7d and 8d) to automatically validate
pins were inserted at the desired locations on a hexagonal grid. Pin diameters were verified manually.
Clinical quality assurance was done by measuring
the relative dose distribution at a 2.0-cm depth in a
water phantom underlying the intensity modulator. The
measurement was compared with PBRA calculations
from the planning system (patient and bolus replaced
with water phantom). Isodose plots are compared for
the chest wall and the temple patients in Figures 9a and
10a, respectively. Regions in which calculated dose exceeds 10%, measured dose differs by 3%, and distance
to agreement (DTA) exceeds 0.3 cm are demarcated.
Only small areas near the superior penumbra of the
chest wall patient field exceeded that criteria, having a
99.9% pass rate; the temple intensity modulator had a
100% pass rate. Also, it should be appreciated that this
QA test not only validates the intensity modulator, but
also the electron cutout.

Another way of evaluating the dose comparisons is
plotting dose difference histograms, which are plotted
in Figures 9b and 10b for the chest wall and temple,
respectively. These result show agreement within approximately (−3%, +5%,) and (−3%, +4%), respectively,
for calculated dose greater than 80%.

4
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D I SCUSS I O N

4.1 | Impact potential of IM-BECT
In IM-BECT the purpose of intensity modulation is to
improve PTV dose homogeneity as compared to BECT,
as first reported by Kudchadker et al.7 For this report,
the two patient cases illustrating the IM-BECT technique were selected based on their having been treated
with BECT and having hot spots in their PTVs. Results
showed IM-BECT to improve dose homogeneity in the
PTV by a modest amount; D90-10 was reduced from
7.3% to 6.4% for the chest wall case and 11.0% to 8.4%
for the temple case, somewhat less than the 14.9% to
9.2% for the buccal mucosa case of Kudchadker et al.7
Generally, electron beam therapy offers the potential
to reduce secondary cancer control probability and
dose to distal structures, the latter being enhanced by
using BECT. IM-BECT offers opportunity for improving
BECT PTV dose homogeneity. Overall, the utility of IM-
BECT will depend upon how much normal tissue dose/
complication probability and secondary cancer control
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F I G U R E 9 (a) For the chest wall
patient, calculated (solid) and measured
(dashed) isodose plots downstream of
the intensity modulator at 2.0-cm depth in
water. Points not meeting the 3% or 3 mm
criteria are highlighted in black (measured
> calculated). (b) For the chest wall
patient, histogram of the dose differences
between the calculated and measured
isodose data. Highlighted in black are the
points receiving <80% of the given dose

F I G U R E 1 0 (a) For the temple
patient, calculated (solid) and measured
(dashed) isodose plots downstream
of the intensity modulator at 2.0-cm
depth in water. All points met the 3% or
3 mm criteria. (b) For the temple patient,
histogram of the dose differences
between the calculated and measured
isodose data. Highlighted in black are the
points receiving <80% of the given dose

probability might be reduced compared to current techniques. This suggests the need for patient studies to
determine which sites might benefit most from IM-
BECT as compared to BECT, IMXT, and other current
techniques.
The primary purpose of the current study was
to expound on a process of using passive intensity
modulators for IM-
BECT by further describing its
planning, fabrication, and quality assurance techniques. As with any new technology, research and
development is an ongoing process, and potential refinements of these individual clinical techniques are
discussed below.

4.2 | Reapplication of IM Operator in IM-
BECT treatment planning
Following application of the intensity modulation operator and bolus redesign, using an earlier research
version of the p.d software (with intensity modulator operator, but without island block segmentation),
Doiron21 showed benefit from one to two or more iterations of reapplying the intensity modulation operator and bolus redesign. The research version of the

p.d software used in the present study included island
block segmentation, but did not allow such further iterations. Hence, the IM-BECT plans in the present study
might not necessarily be optimal, but were suitable for
illustrating IM-BECT planning, fabrication, and quality
assurance techniques. Future versions of IM-
BECT
software will include such capability prior to clinical
release. Also, clinical use might be further improved
through research and development of methods for simultaneous optimization of bolus and intensity modulator design.

4.3 | Quality assurance of
intensity modulators
The factory QA process verified proper fabrication of
the intensity modulator, that is, that island blocks are in
the proper locations with the proper diameters. The locations were determined using computer software and
an optical scanned image of the intensity modulator,
and the diameters were verified manually; however, as
the number of fabricated intensity modulators increases
and prior to clinical release, software to determine island block diameters will be implemented.
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Regarding the clinical QA process, clinical pass rates
should be studied using a diode or ion chamber matrix,
as such measurement techniques are more standard
and practical than a beam scanning water phantom
system. Also, a number of intensity modulators should
be studied to better determine passing criteria and
rates using current methods or gamma analysis and
to investigate their dependence on minimum IRF and
patient site.

4.4 | Accuracy of PBRA dose
calculation
Small differences between measured and calculated
doses is expected due to the current PBRA calculation assuming perfect island block collimation, that is,
scatter into and from the sides of the block has not
been modeled. Preliminary data of Hilliard20 and more
recent ongoing measurements showed PBRA calculations can underestimate measurements at 0.5 and
2.0 cm depths by as much as 5% in the energy range
of 7–20 MeV for a large array of island blocks that create an IRF of 60%. Such extreme modulation is highly
unlikely for IM-BECT, hence this assumption had little
impact on the accuracy of the PBRA calculated dose
in the current study, as illustrated by the QA results.
However, for other applications, this might not always
be the case; therefore, scatter into and from the sides
of the island blocks is being investigated further and in
the future will be modeled in the PBRA.

4.5 | Clinical Implementation
Clinical implementation of IM-BECT is envisioned as
an addition to the BECT process, which has been clinically available for over a decade. The BECT process,
as implemented by .decimal (Sanford, FL), uses an
external software (p.d) to design the patient-specific
bolus, which once designed is transferred to the clinic's
treatment planning system as a structure for use in calculating the final dose plan. In parallel the bolus design
is transmitted to .decimal for fabrication. The fabricated
bolus is sent to the clinic, where its construction is typically verified by performing a dose calculation using a
CT scan with the fabricated bolus in place. Other steps
such as collimator fabrication, MU calculations are the
same as for an electron beam therapy treatment without conformal bolus. This incremental process can be
completed in a 2–3 day time frame.
IM-
BECT is a BECT treatment with the addition
of an intensity modulator; however, there are significant changes to the process. First, IM-BECT must be
planned by an electron planning system that can design
intensity modulators and compute dose for electron
beams with intensity modulation, a feature unavailable
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in current treatment planning systems. Such a commercial system is currently under development. Because
intensity modulation is designed in conjunction with
bolus design, required planning time should have insignificant increase. Second, the intensity modulator
requires fabrication, which is done in parallel with bolus
fabrication, adding no increase to the pretreatment
time. As the intensity modulator is rigidly embedded in
the electron cutout, the cutout must be fabricated as
part of the intensity modulator fabrication process. This
is consistent with the concept that the cutout is an intensity modulator transmitting a relative electron fluence of
unity inside and zero outside its aperture. Third, once
received, QA of the intensity modulator and cutout can
be performed using the methodology discussed earlier.
This step could increase the time to treatment by a day.
To clinically implement IM-BECT, staff competence in
electron beam therapy, understanding of the IM-BECT
process and its clinical utility, availability of an IM-
BECT planning system, and access to a 2D matrix detector like MapCHECK for intensity modulator QA are
required competencies and equipment.

4.6 | Failure mode and effects analysis
(FMEA)
As IM-BECT modulates range (energy) and intensity
versus off-
axis position using physical boluses and
intensity modulators, respectively, it provides a significantly advanced electron beam therapy technology,
which is comparable to advanced x-
ray and proton
therapies. Although QA procedures exist for BECT and
additional ones are presented here for IM-BECT, both
modalities could benefit from a study of its workflow
using FMEA analysis.31 FMEA analyzes have been
reported for special electron techniques, such as total
skin electron therapy32 and intraoperative electron
therapy,33,34 and the IM-BECT workflow process reported here could benefit from such analysis once all
steps are finalized and an initial commercial product
becomes clinically available.

5 | SUM M A RY A ND
FUTUR E D E V ELO PM ENT
This work describes and demonstrates for the first
time techniques comprising a clinical process for intensity modulated bolus electron conformal therapy
(IM-BECT), which is an expansion of the process for
bolus electron conformal therapy (BECT). It describes
how (1) an intensity map operator is integrated into the
BECT treatment planning process, (2) an intensity map
is converted (segmented) into a set of island blocks that
comprise the intensity modulator, (3) the PBRA dose
algorithm is modified to compute dose in the presence
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of the intensity modulator, (4) the intensity modulator is
fabricated, and (5) how quality assurance is performed
at the factory and the clinic. This process was demonstrated for two patient examples, both previously
treated using BECT, one a postmastectomy chest wall
and one a temple.
The demonstration illustrates the feasibility for
having an efficient, potentially economical method
for delivering IM-BECT using existing electron beam
treatment machines. Software for planning IM-BECT,
which requires modifications to current clinically available BECT software (p.d) and interfacing it to other
treatment planning systems, has been produced in a
research capacity and is currently being further developed as part of an NIH SBIR grant for technology
transfer. Also, factory fabrication of patient-specific intensity modulators has been demonstrated, as have
methods for factory and clinical quality assurance. As
part of an NIH SBIR grant, improvements to the PBRA
dose calculation, improvements to the factory quality
assurance process, and methods for improving efficiency and setting thresholds for clinical quality assurance are being researched and developed. Also, as
part of the grant and as this technology becomes available, its clinical utility will be studied, that is, which patient sites and characteristics might benefit most from
IM-BECT as compared to existing BECT and IMXT.
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